Other languages Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
14.92 ^USD	+12.94%		-0.27%	+2.19%

04-24	Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	MT
04-24	Transcript : Day One Biopharmaceuticals, Inc. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma	04-23
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment	04-23
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing	02-29
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-26
Day One Biopharmaceuticals, Inc. Announces Executive Changes	02-26
Day One Biopharmaceuticals, Inc. Announces Board Appointments	01-17
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	23-10-31
Sector Update: Health Care Stocks Gain Late Afternoon	23-10-30
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-10-30
Day One Biopharmaceuticals' New Drug Application for Tovorafenib Granted Priority Review by FDA	23-10-30
Day One Biopharmaceuticals, Inc. Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma	23-10-30
Day One Biopharmaceuticals Files Mixed Shelf	23-09-15
Sector Update: Health Care Stocks Higher Monday Afternoon	23-09-11
Day One Completes Rolling Submission of New Drug Application for Pediatric Brain Tumor Drug	23-09-11
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling Nda Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma	23-09-11
Day One Biopharmaceuticals, Sprint Bioscience Sign Exclusive License, Research Deal	23-08-16
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
Day One Biopharmaceuticals Prices $150 Million Common Stock Offering	23-06-07
Day One Biopharmaceuticals Launches Public Offering of $150 Million in Shares	23-06-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Other languages

Filters